预约演示

更新于：2025-05-07

Tamsulosin Hydrochloride

盐酸坦洛新

更新于：2025-05-07

概要

基本信息

简介坦索罗辛于1997年在美国被批准用于医疗用途。具体而言，它是一种α1肾上腺素能受体阻滞剂。以 Flomax 等品牌名称销售的坦索罗辛是一种用于治疗症状性良性前列腺增生 (BPH) 和慢性前列腺炎并帮助排出肾结石的药物。当结石较大时，肾结石获益的证据更好。它是通过嘴巴服用的。常见的副作用包括头晕、头痛、失眠、恶心、视力模糊和性问题。其他副作用可能包括站立时头晕目眩和血管性水肿。坦索罗辛是一种α受体阻滞剂，通过放松前列腺肌肉起作用。坦索罗辛于1997年在美国被批准用于医疗用途。具体而言，它是一种α1肾上腺素能受体阻滞剂。以 Flomax 等品牌名称销售的坦索罗辛是一种用于治疗症状性良性前列腺增生 (BPH) 和慢性前列腺炎并帮助排出肾结石的药物。当结石较大时，肾结石获益的证据更好。它是通过嘴巴服用的。常见的副作用包括头晕、头痛、失眠、恶心、视力模糊和性问题。其他副作用可能包括站立时头晕目眩和血管性水肿。坦索罗辛是一种α受体阻滞剂，通过放松前列腺肌肉起作用。

药物类型

小分子化药

别名

(-)-tamsulosin、(R)-(-)-tamsulosin、(R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide

+ [36]

靶点

α1A-AR

作用方式

拮抗剂

作用机制

α1A-AR拮抗剂(肾上腺素能受体α-1a拮抗剂)

治疗领域

泌尿生殖系统疾病其他疾病

在研适应症

下尿路症状前列腺增生症

非在研适应症

急性尿潴留排尿困难勃起功能障碍+ [5]

原研机构

Astellas Pharma, Inc.

在研机构

Astellas Pharma Europe BV

Astellas Pharma, Inc.Astellas Pharma Australia Pty Ltd.

+ [2]

非在研机构

Boehringer Ingelheim GmbH

安斯泰来制药（中国）有限公司Astellas Pharma Europe Ltd.

+ [1]

权益机构

青岛百洋医药股份有限公司

Astellas Pharma, Inc.

最高研发阶段批准上市

首次获批日期

日本 (1993-07-02),

前列腺增生症

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C20H29ClN2O5S

InChIKeyZZIZZTHXZRDOFM-XFULWGLBSA-N

CAS号106463-17-6

查看全部结构式(2)

关联

316

项与盐酸坦洛新相关的临床试验

NCT06803030

/ Not yet recruiting临床3期IIT

A Comparative Study on the Efficacy of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms: a Randomized Controlled Trial

A comparative study on the efficacy of Tamsulosin, Solifenacin and Mirabegron in alleviating ureteral stent-related symptoms: a randomized controlled trial.

开始日期2025-04-01

申办/合作机构

Bir Hospital

NCT06865430

/ RecruitingN/AIIT

Management of Dysuria and Irritative Symptoms After HoLEP: a Prospective Study Evaluating the Efficacy of Alpha-Blocker Therapy

Holmium Laser Enucleation of the Prostate (HoLEP) is an increasingly popular endoscopic minimally invasive surgical technique for the treatment of benign prostatic hyperplasia (BPH). In the literature, the long-term efficacy and low complication rates of HoLEP have been highlighted in many studies. However, in the early postoperative period, particularly within the first three months, irritative symptoms are reported in 17-35% of cases (1-2).
The pathophysiology of postoperative irritative symptoms is not yet fully understood, but it has been suggested that these symptoms may be associated with urethral trauma, the mucosal healing process, and detrusor overactivity. These symptoms can significantly impact quality of life, reducing patient satisfaction. In particular, dysuria is a frequently encountered symptom after HoLEP, with considerable individual variability in its severity and duration.
The effectiveness of alpha-blockers in alleviating postoperative dysuria and irritative symptoms remains a topic of debate in the literature. Although prostate tissue is surgically removed, alpha-blockers may improve urinary flow and relieve symptoms associated with bladder outlet obstruction by reducing urethral smooth muscle tone (3). Studies on the use of alpha-blockers following transurethral resection of the prostate (TURP) have shown limited postoperative benefits (4). However, to the best of our knowledge, no study has specifically evaluated their use following HoLEP, an enucleation-based technique. Therefore, further studies are needed to assess the role of alpha-blockers in managing dysuria after HoLEP.
The aim of this study is to evaluate the effectiveness of alpha-blocker therapy in managing dysuria and other irritative symptoms following HoLEP. Additionally, the study seeks to determine the impact of this treatment on quality of life and patient satisfaction.

开始日期2025-03-04

申办/合作机构-

NCT06843538

/ Recruiting临床3期

Peri-operative Tamsulosin and Impact on Voiding Trial Following Outpatient Urogynecology Surgery: a Randomized Controlled Trial

The purpose of this research study is to determine if taking tamsulosin preoperatively decreases your chances of being discharged after surgery with a Foley catheter (flexible tube that drains urine from the bladder into a collection bag).

开始日期2025-02-03

申办/合作机构

TriHealth, Inc.

100 项与盐酸坦洛新相关的临床结果

登录后查看更多信息

100 项与盐酸坦洛新相关的转化医学

登录后查看更多信息

100 项与盐酸坦洛新相关的专利（医药）

登录后查看更多信息

3,207

项与盐酸坦洛新相关的文献（医药）

2025-07-01·American Journal of Ophthalmology

Drugs Associated With Floppy Iris Syndrome: A Real-World Population-Based Study

Article

作者: Muni, Rajeev H ; Lakhani, Moiz ; Kwan, Angela T H ; Hurley, Bernard ; Popovic, Marko M ; Mihalache, Andrew

PURPOSEIntraoperative floppy iris syndrome (IFIS) is associated with an increased rate of severe intraoperative complications and greater visual morbidity during cataract surgery, particularly in females. To date, no postmarketing pharmacovigilance study has comprehensively examined all FDA-approved drugs for their association with IFIS development or explored potential sex differences. Understanding the risk factors for IFIS allows cataract surgeons to better stratify surgical risks and implement appropriate preoperative and intraoperative measures to ensure adequate management in high-risk patients.DESIGNRetrospective pharmacovigilance clinical cohort study.METHODSThis population-based, observational study analyzed IFIS cases reported to the Food and Drug Administration Adverse Event Reporting System from October 2003 to March 2024 using OpenVigil 2.1. Disproportionality metrics, including reporting odds ratios (RORs), proportional reporting ratios (PRRs), and relative risk reductions, were used to assess signals for positive adverse reactions (n > 2, χ² > 4, PRR > 2), compared to all other drugs. Subgroup analyses were also conducted by sex.RESULTSOf 12,345,128 adverse event reports, 649 (0.0053%) involved IFIS. The majority of cases were reported by healthcare professionals (75.75%, n = 203), followed by consumers (12.69%, n = 34) and unknown sources (11.57%, n = 31). Drugs with the highest disproportionality for IFIS included imipramine (ROR = 251.66, 95% confidence interval [CI] = 157.53-402.02), tamsulosin (ROR = 171.44, 95% CI = 143.12-205.36), and chlorpromazine (ROR = 91.30, 95% CI = 49.91-167.03) (all P < .0001, IC₀₂₅ > 0). Over-reported drug classes included α1-blockers, tricyclic antidepressants, atypical antipsychotics, carbonic anhydrase inhibitors, corticosteroids, 5α-reductase inhibitors, β-blockers, prostaglandin analogs, and β2-agonists. Among females, brinzolamide (ROR = 409.63, 95% CI = 196.78-852.73) and salbutamol (ROR = 67.12, 95% CI = 28.37-158.80) were disproportionately associated with IFIS (both P < .0001, IC₀₂₅ > 0), whereas these associations were not observed in males.CONCLUSIONSThis analysis of over 20,000 drugs and 12 million reports highlights that, in addition to α1-blockers and atypical antipsychotics, tricyclic antidepressants are among the key agents most disproportionately associated with IFIS, with notable sex differences. These findings are crucial for informing perioperative counseling and surgical planning for cataract surgery.

2025-06-01·Journal of Molecular Liquids

Volumetric and sonometric properties of ionic aminated resorcin[4]arenes in water and DMSO at 278.15 K to 303.15 K

作者: Hefter, Glenn ; Espitia-Galindo, Nicolas ; Vargas, Edgar F.

Understanding supramol. chem. requires comprehensive knowledge of macrocycle behavior in solutionThis study reports standard molar volumes and compressibilities of the chloride salts of two cationic macrocycles C-methylresorcin[4]arene-tetraminoethylated-hydrochloride (TAE·(HCl)₄) and their C-Et analog (ETAM·(HCl)₄) in aqueous and DMSO solutionsThese quantities were obtained using d. and speed of sound measurements at concentrations (0.005 to 0.08) mol·kg^-1 and temperatures in the range (278.15 to 308.15) K.NMR techniques were used to study the structures of the macrocycles in solution, while the corresponding compounds were characterised using mass spectrometry, thermogravimetry and differential scanning calorimetry.The partial molar quantities derived from the volumetric and sonometric data are discussed, along with relevant literature information, in terms of solute-solvent interactions.Structural modifications of macrocycles influence the standard molar compressibilities through changes in solvent organization around functional groups, intrinsic compressibility, and water mols. in the resorcinarene cavity.The effect of carbon chain length on the volumes and compressibilities of substituted resorcin[4]arenes is shown to depend on their location in the macrocycle, but not on the solvent.The standard molar volume is shown to be influenced by ionic moieties and intramol. hydrogen bonds.

2025-06-01·American Journal of Ophthalmology

Unplanned Return to the Operating Room After Cataract Surgery

Article

作者: Ali, Muhammad ; Khan, Malik Muhammad Hamza ; Akhlaq, Anam ; Schein, Oliver D ; Woreta, Fasika A ; Suazo, Mallory K

PURPOSETo determine the rate of unplanned return to the operating room (OR) within 90 days of cataract surgery and to identify the most common preoperative and intraoperative risk factors.DESIGNRetrospective case-control study.SUBJECTS AND CONTROLSPatients aged ≥40 years undergoing cataract surgery at the Wilmer Eye Institute between 2019 and 2022 with at least 90 days of postoperative follow-up were included. Patients with return to the OR for a reason other than a postoperative complication of cataract surgery in the same eye were excluded. For each case, a time-matched control (cataract surgery within 1 month of the case's surgery) was selected using a random number generator.METHODSThe chi-squared test was used for categorical variables, the student's t-test for continuous variables, and the multivariable logistic regression analysis to assess for associated preoperative and intraoperative factors.MAIN OUTCOME MEASURESThe main outcomes included the rate and the most common reasons for unplanned return to the OR as well as the odds ratios of associated preoperative and intraoperative variables.RESULTSAmong 32,480 eyes, 175 eyes (0.54%) had an unplanned return to the OR within 21 ± 21 days of cataract surgery. The most common reason was retained lens fragments in 88 eyes (50%). Patients with an unplanned return to the OR had a worse mean best-corrected visual acuity preoperatively (Snellen equivalent of ∼20/100 for cases vs 20/50 for controls, p-value < .001) and at last follow-up (cases 20/50, controls 20/30, p-value < .001). There were significantly higher odds of an unplanned return to the OR for patients undergoing complex cataract surgery (odds ratio, 1.80; 95% CI, 1.06-3.05) and for patients with prior tamsulosin use (odds ratio, 2.00; 95% CI, 1.09-3.69).CONCLUSIONSPatients undergoing complex cataract surgery and those with prior tamsulosin use had significantly higher odds of unplanned return to the OR. Monitoring rates of unplanned return to the OR at the institutional and national levels by using national clinical registries or a multicenter study is needed to assist in quality monitoring and to improve patient surgical outcomes.

项与盐酸坦洛新相关的新闻（医药）

2025-05-01

·ioncology

前列腺癌放疗相关毒副反应的预防和处理原则

前列腺癌治疗过程中，放疗与手术并列作为重要的局部治疗手段。但放射性损伤可能影响患者生活质量。本文结合最新研究和临床实践，梳理放射性损伤的预防策略及处理要点。01 放射性损伤的预防策略精准定位与放疗计划优化前列腺癌治疗过程中，放疗与手术并列作为重要的局部治疗手段。但放射性损伤可能影响患者生活质量。本文结合最新研究和临床实践，梳理放射性损伤的预防策略及处理要点。操作要点：定位及放疗前要求患者排空直肠、适度充盈膀胱（建议治疗前1小时饮水250-300ml），且尽量做到每次保持一致状态；有条件的话，可考虑采用前列腺直肠隔离技术进一步降低直肠受量。水化与饮食管理心、肾功能正常的患者，建议每日饮水量≥2000ml，维持尿量稀释以保护膀胱黏膜。饮食建议：高蛋白、高维生素（如维生素C/E），避免辛辣、产气食物（如牛奶、豆类）。功能锻炼与生活方式干预指导患者进行膀胱训练（定时排尿、延长排尿间隔），规律进行适当的盆底肌功能锻炼（如凯格尔运动），可帮助预防和改善尿失禁症状。鼓励适度有氧运动（如散步、游泳）以增强体质，降低疲劳感。02 放射性损伤的处理原则泌尿系统损伤（放射性膀胱炎）症状尿频、尿急、血尿等。大多数患者可自愈。生活方式多饮水稀释尿液，避免辛辣食物及憋尿。减少增加腹压的动作（如提重物、剧烈咳嗽）。纠正、避免便秘。治疗方法口服维生素C/K增强血管强度，严重出血使用止血敏或前列腺素类药物。导尿管膀胱冲洗。膀胱灌注凝血酶、硝酸银或去甲肾上腺素。高压氧治疗（HBOT）：促进血管新生和黏膜修复，适用于持续性出血。髂内动脉栓塞控制大出血，尿流改道。泌尿系统损伤（尿失禁）生活方式避免摄入咖啡、酒精等利尿物质，控制饮水量（少量多次）。减少增加腹压的动作（如提重物、剧烈咳嗽）。保守治疗盆底肌康复训练（Kegel运动）每日3~4组收缩-放松训练（每组10~15次），增强尿道括约肌力量。药物治疗抗胆碱药（如索利那新），减少膀胱过度活动。α受体阻滞剂（如坦索罗辛），松弛膀胱颈平滑肌，改善排尿阻力。进阶方案生物反馈电刺激治疗，提高训练效率。肠道损伤（放射性直肠炎）症状腹泻、里急后重、便血。饮食调整放疗期间推荐低纤维、低脂、高蛋白饮食，避免辛辣、油腻食物；维持肠道通畅。便后温水清洁肛周，使用皮肤保护剂（如氧化锌软膏）预防肛周皮肤损伤。药物治疗抗炎与黏膜修复：可应用美沙拉嗪、柳氮磺胺吡啶抑制炎症反应；瑞巴派特灌肠促进黏膜修复。止血与症状控制：沙利度胺对顽固性出血有效；止泻药（如洛哌丁胺）缓解腹泻。调节菌群：双歧杆菌等益生菌制剂可维持肠道菌群平衡，减轻炎症反应。局部治疗灌肠疗法：丁酸钠、短链脂肪酸灌肠减轻黏膜炎症；激素灌肠（如氢化可的松）短期缓解急性症状。内镜下治疗：氩离子凝固术（APC）用于止血和修复溃疡；福尔马林局部烧灼治疗顽固性出血，需在内镜引导下操作以避免并发症。高压氧治疗（HBOT）温和、有效的治疗方式。通过提高组织氧分压，促进血管新生和黏膜修复，尤其适用于慢性放射性直肠炎。皮肤反应与骨髓抑制皮肤反应干性脱皮时使用无刺激性润肤剂，湿性皮炎采用银离子敷料。骨髓抑制每周监测血常规，医生根据具体情况决定药物治疗策略。远期并发症管理尿道狭窄/膀胱挛缩定期尿流率检查，必要时行尿道扩张术。性功能障碍早期心理干预，PDE5抑制剂改善勃起功能。03 多学科协作与随访放疗中联合营养科等多学科制定个体化饮食及生活方式建议，心理科疏导焦虑情绪。放疗后放疗后1个月、2年内每3个月、5年内每6个月进行复查，之后每年复查。如PSA快速上升或生化失败，需进行影像学检查。在肿瘤学定期复查的同时，须关注患者的晚期毒副反应。04 结语大多数前列腺癌患者可通过放疗、手术、药物治疗等综合治疗手段得以治愈。随着前列腺癌患者生存期的逐渐延长，治疗相关毒副反应的预防与治疗成为本领域的研究热点。北大医院泌尿肿瘤综合治疗团队通过精准放疗技术、全程健康管理及生活方式指导，不断降低前列腺癌治疗相关毒副反应的发生概率，希望通过我们的努力可以持续改善患者长期生活质量，让前列腺癌患者活得更长、活得更好！*本文内容综合自国内外前列腺癌放疗指南及临床研究。图文：李山湜审阅：李洪振审核：放疗科

放射疗法

2025-04-28

·信狐药迅

江苏奥赛康利厄替尼用于一线非小肺癌、中山康方依若奇单抗用于银屑病获批上市| 新获批(4.21-4.27）

每周药品注册获批数据，分门别类呈现，一目了然。(4.21-4.27）新药上市申请药品名称企业注册分类受理号利厄替尼片江苏奥赛康药业有限公司1CXHS2400074奥布替尼片北京诺诚健华医药科技有限公司2.4CXHS2400078依若奇单抗注射液中山康方生物医药有限公司1CXSS2300069特瑞普利单抗注射液上海君实生物医药科技股份有限公司2.2CXSS2400085特瑞普利单抗注射液上海君实生物医药科技股份有限公司2.2CXSS2400084依沃西单抗注射液康方赛诺医药有限公司2.2CXSS2400080新药临床申请药品名称企业注册分类受理号GST-HG131片福建广生中霖生物科技有限公司1CXHL2500295GST-HG131片福建广生中霖生物科技有限公司1CXHL2500294奈瑞可韦片福建广生中霖生物科技有限公司1CXHL2500293奈瑞可韦片福建广生中霖生物科技有限公司1CXHL2500292注射用ALK-N001浙江昂利康制药股份有限公司1CXHL2500201VC005片江苏威凯尔医药科技股份有限公司1CXHL2500200HEC-007注射液广东东阳光药业股份有限公司1CXHL2500199HEC-007注射液东莞市东阳光生物药研发有限公司1CXHL2500198SAL0140片深圳信立泰药业股份有限公司1CXHL2500196SAL0140片深圳信立泰药业股份有限公司1CXHL2500195AHB-137注射液杭州浩博医药有限公司1CXHL2500193MT-1207缓释片原研药港生命科学(辽宁)集团有限公司1CXHL2500191MT-1207缓释片原研药港生命科学(辽宁)集团有限公司1CXHL2500190MT-1207缓释片原研药港生命科学(辽宁)集团有限公司1CXHL2500189HIF-117胶囊沈阳三生制药有限责任公司1CXHL2500179HIF-117胶囊沈阳三生制药有限责任公司1CXHL2500178HIF-117胶囊沈阳三生制药有限责任公司1CXHL2500177TJ0113胶囊杭州天玑济世生物科技有限公司1CXHL2500180HRS-5635注射液福建盛迪医药有限公司1CXHL2500174HS-10542胶囊江苏豪森药业集团有限公司1CXHL2500165HS-10542胶囊江苏豪森药业集团有限公司1CXHL2500163HS-10542胶囊江苏豪森药业集团有限公司1CXHL2500161SYH2068注射液石药集团中诺药业(石家庄)有限公司1CXHL2500173HS-10542胶囊江苏豪森药业集团有限公司1CXHL2500162UA026片祐森健恒生物医药(上海)有限公司1CXHL2500176UA026片祐森健恒生物医药(上海)有限公司1CXHL2500175FNX010片成都凡诺西生物医药科技有限公司1CXHL2500167FNX010片成都凡诺西生物医药科技有限公司1CXHL2500166HS-10542胶囊江苏豪森药业集团有限公司1CXHL2500164HS-10542胶囊江苏豪森药业集团有限公司1CXHL2500160SK-09片广州康臣药业有限公司1CXHL2500150SK-09片广州康臣药业有限公司1CXHL2500149SNK-2726注射液施能康医药科技(苏州)有限公司1CXHL2500135伊匹乌肽滴眼液温州益承睛湛生物科技有限公司1CXHL2500146HX9428片福建海西新药创制股份有限公司1CXHL2500117HX9428片福建海西新药创制股份有限公司1CXHL2500116硫酸心舒帕莎片山东齐都药业有限公司1CXHL2500102硫酸心舒帕莎片山东齐都药业有限公司1CXHL2500101BTS0327江苏诺和必拓新药研发有限公司2.2CXHL2500192TTYP01片上海澳宗生物科技有限公司2.2CXHL2500159YHAX北京阳光诺和药物研究股份有限公司2.2CXHL2500158注射用WE010上海宝龙药业股份有限公司2.2CXHL25001331640A干混悬剂微多安药业(山东)有限公司2.2CXHL2500115PA9060乳膏安徽劳斯多斯医药科技有限公司2.2;2.4CXHL2500188PA9060乳膏安徽劳斯多斯医药科技有限公司2.2;2.4CXHL2500186KEM2111凝胶贴膏深圳珐玛易药品科技有限公司2.2;2.4CXHL2500172KEM2111凝胶贴膏深圳珐玛易药品科技有限公司2.2;2.4CXHL2500171KEM2111凝胶贴膏深圳珐玛易药品科技有限公司2.2;2.4CXHL2500170DYTH201片山西德元堂药业有限公司2.3CXHL2500184DYTH201片山西德元堂药业有限公司2.3CXHL2500183注射用CS5001基石药业(苏州)有限公司1CXSL2500169PM8002注射液普米斯生物技术(珠海)有限公司1CXSL2500164伏欣奇拜单抗注射液长春金赛药业有限责任公司1CXSL2500163重组人源化抗HER2双特异性抗体注射液上海津曼特生物科技有限公司1CXSL2500160注射用JSKN003上海津曼特生物科技有限公司1CXSL2500159注射用SHR-A2102苏州盛迪亚生物医药有限公司1CXSL2500158注射用SHR-A1904苏州盛迪亚生物医药有限公司1CXSL2500156注射用SHR-A2009苏州盛迪亚生物医药有限公司1CXSL2500155注射用SHR-1826苏州盛迪亚生物医药有限公司1CXSL2500151注射用IBB0979盛禾(中国)生物制药有限公司1CXSL2500150注射用MK-3120默沙东研发(中国)有限公司1CXSL2500148注射用BAT7111百奥泰生物制药股份有限公司1CXSL2500140注射用ESG406上海诗健生物科技有限公司1CXSL2500143注射用XTL6001上海西泰利生物医药科技有限公司1CXSL2500142GZR102甘李药业山东有限公司1CXSL2500134注射用KJ103上海宝济药业股份有限公司1CXSL2500128DNTH103注射液元羿生物科技(上海)有限公司1CXSL2500124NCR201注射液中盛溯源(广州)生物科技有限公司1CXSL2500126注射用BL-B01D1成都百利多特生物药业有限责任公司1CXSL2500117注射用BL-M11D1成都百利多特生物药业有限责任公司1CXSL2500105注射用RC108荣昌生物制药(烟台)股份有限公司1CXSL2500108注射用LBL-024南京维立志博生物科技股份有限公司1CXSL2500107注射用LBL-024南京维立志博生物科技股份有限公司1CXSL2500106注射用ZG006苏州泽璟生物制药股份有限公司1CXSL2500122注射用BL-B01D1成都百利多特生物药业有限责任公司1CXSL2500114注射用BL-B01D1成都百利多特生物药业有限责任公司1CXSL2500119XS228细胞注射液士泽生物医药(苏州)有限公司1CXSL2500121重组抗人EGFR抗体/IL-10双特异Fc融合蛋白注射液施慧达药业集团(吉林)有限公司1CXSL2500098JMT601注射液上海津曼特生物科技有限公司1CXSL2500091人羊膜间充质干细胞注射液源品细胞生物科技集团有限公司1CXSL2500087人自体多克隆调节性T细胞注射液上海赛尔欣生物医疗科技有限公司1CXSL2500094RY_SW01细胞注射液江苏睿源生物技术有限公司1CXSL2500082RGL-270注射液广州瑞领医药有限公司1CXSL2500080UTAA09注射液博生吉医药科技(苏州)有限公司1CXSL2500075FT-017注射液芳拓生物科技(上海)有限公司1CXSL2500078TriCellPr-AC07人脐带间充质干细胞注射液奥辰生物(云南)有限公司1CXSL2500071IBR854细胞注射液英百瑞(杭州)生物医药有限公司1CXSL2500065SHR-1316(sc)注射液苏州盛迪亚生物医药有限公司2.1CXSL2500170阿得贝利单抗注射液上海盛迪医药有限公司2.2CXSL2500157贝伐珠单抗注射液苏州盛迪亚生物医药有限公司2.2CXSL2500153SHR-8068注射液苏州盛迪亚生物医药有限公司2.2CXSL2500152阿得贝利单抗注射液上海盛迪医药有限公司2.2CXSL2500109纳基奥仑赛注射液广东合源生物医药有限公司2.2CXSL2500076仿制药申请药品名称企业注册分类受理号硫酸沙丁胺醇注射液湖南华纳大药厂股份有限公司3CYHS2400290二羟丙茶碱注射液四川美大康华康药业有限公司3CYHS2400067帕拉米韦注射液石药银湖制药有限公司3CYHS2400009洛索洛芬钠口服溶液重庆华邦制药有限公司3CYHS2303660吲哚布芬片浙江百代医药科技有限公司3CYHS2303413注射用比阿培南江苏睿实生物科技有限公司3CYHS2303286维生素K1注射液海南倍特药业有限公司3CYHS2303088维生素K1注射液海南倍特药业有限公司3CYHS2303087多种微量元素注射液(I)合肥市未来药物开发有限公司3CYHS2303078氯化钾口服溶液成都倍特得诺药业有限公司3CYHS2303071氯化钾口服溶液成都倍特得诺药业有限公司3CYHS2303070草酸艾司西酞普兰口服溶液苏州朗科生物技术股份有限公司3CYHS2302987多索茶碱片浙江高跖医药科技股份有限公司3CYHS2302945多索茶碱片浙江高跖医药科技股份有限公司3CYHS2302944喷他佐辛注射液天津药物研究院药业有限责任公司3CYHS2302846磷酸奥司他韦干混悬剂葵花药业集团(衡水)得菲尔有限公司3CYHS2302832磷酸奥司他韦干混悬剂遂成药业股份有限公司3CYHS2302767生理氯化钠溶液黑龙江博宇制药有限公司3CYHS2302734生理氯化钠溶液黑龙江博宇制药有限公司3CYHS2302733注射用盐酸罗沙替丁醋酸酯湖北午时医药研究院有限公司3CYHS2302671昂丹司琼口溶膜四川科伦药业股份有限公司3CYHS2302670昂丹司琼口溶膜四川科伦药业股份有限公司3CYHS2302669醋氯芬酸片河南诺美药业有限公司3CYHS2302640萘普生钠软胶囊人福普克药业(武汉)有限公司3CYHS2302595醋酸钠林格葡萄糖注射液仁合益康集团有限公司3CYHS2302597普瑞巴林口服溶液山东新华制药股份有限公司3CYHS2302592氨氯地平贝那普利胶囊地奥集团成都药业股份有限公司3CYHS2302581硫酸镁注射液云南药科院生物医药股份有限公司3CYHS2302580美索巴莫注射液苏州特瑞药业股份有限公司3CYHS2302559美索巴莫注射液浙江华海药业股份有限公司3CYHS2302547依帕司他片中山万汉制药有限公司3CYHS2302544盐酸美金刚口服溶液山东新华制药股份有限公司3CYHS2302462己酮可可碱注射液海南普利制药股份有限公司3CYHS2302430米诺地尔外用溶液江苏睿实生物科技有限公司3CYHS2302268米诺地尔外用溶液江苏睿实生物科技有限公司3CYHS2302267尼莫地平口服溶液海南全星制药有限公司3CYHS2302210盐酸丙卡特罗口服溶液遂成药业股份有限公司3CYHS2302178盐酸丙卡特罗口服溶液遂成药业股份有限公司3CYHS2302177酮咯酸氨丁三醇注射液聊城高新生物技术有限公司3CYHS2302133酮咯酸氨丁三醇注射液聊城高新生物技术有限公司3CYHS2302132米诺地尔搽剂广东泉新泉益药业有限公司3CYHS2302063米诺地尔搽剂广东泉新泉益药业有限公司3CYHS2302062盐酸氨溴索口服溶液江苏晨牌药业集团股份有限公司3CYHS2302014地氯雷他定口服溶液浙江普利药业有限公司3CYHS2302024盐酸肾上腺素注射液山西振东泰盛制药有限公司3CYHS2301996注射用盐酸罗沙替丁醋酸酯国药集团国瑞药业有限公司3CYHS2301988美索巴莫注射液江苏艾立康医药科技有限公司3CYHS2301826马来酸噻吗洛尔滴眼液合肥立方制药股份有限公司3CYHS2301833地氯雷他定口服溶液安徽四环科宝制药有限公司3CYHS2301562地氯雷他定口服溶液安徽四环科宝制药有限公司3CYHS2301561米诺地尔外用溶液美罗药业股份有限公司3CYHS2301537米诺地尔外用溶液美罗药业股份有限公司3CYHS2301536米诺地尔搽剂常州四药制药有限公司3CYHS2301247米诺地尔外用溶液深圳市朗博生物医药股份有限公司3CYHS2300960羧甲司坦口服溶液浙江易泽达医药科技有限公司3CYHS2300805富马酸福莫特罗吸入溶液湖南科伦制药有限公司3CYHS2300661复方醋酸钠林格注射液西藏多瑞医药股份有限公司3CYHS2300437复方醋酸钠林格注射液西藏多瑞医药股份有限公司3CYHS2300436复方醋酸钠林格注射液广东大翔制药有限公司3CYHS2201674国;CYHS2201674复方醋酸钠林格注射液广东大翔制药有限公司3CYHS2201673国;CYHS2201673注射用氢化可的松琥珀酸钠天津金耀药业有限公司3CYHS2201560国;CYHS2201560注射用氢化可的松琥珀酸钠天津金耀药业有限公司3CYHS2201559国;CYHS2201559精氨酸布洛芬颗粒石家庄四药有限公司4CYHS2401074普伐他汀钠片浙江诺得药业有限公司4CYHS2400962普伐他汀钠片浙江诺得药业有限公司4CYHS2400961聚乙烯醇滴眼液四川海梦智森生物制药有限公司4CYHS2400757亚叶酸钙注射液江苏瑜兴医药科技有限公司4CYHS2400742依折麦布辛伐他汀片浙江诺得药业有限公司4CYHS2400720枸橼酸托瑞米芬片重庆士立德医药科技有限公司4CYHS2400644枸橼酸托瑞米芬片重庆士立德医药科技有限公司4CYHS2400643达格列净二甲双胍缓释片(Ⅰ)石家庄四药有限公司4CYHS2400538阿戈美拉汀片北京海步医药科技有限公司4CYHS2400562瑞舒伐他汀依折麦布片(I)北京福元医药股份有限公司4CYHS2400519普拉洛芬滴眼液江苏广承药业有限公司4CYHS2400437非诺贝特酸胆碱缓释胶囊华润双鹤药业股份有限公司4CYHS2400438盐酸决奈达隆片江西科睿药业有限公司4CYHS2400430地夸磷索钠滴眼液郑州维先医药科技有限公司4CYHS2400397地夸磷索钠滴眼液郑州维先医药科技有限公司4CYHS2400396盐酸戊乙奎醚注射液广西科伦制药有限公司4CYHS2400366盐酸氮卓斯汀滴眼液广州市桐晖药业有限公司4CYHS2400268磷酸西格列汀片四川益生智同医药生物科技发展有限公司4CYHS2400202间苯三酚注射液河南敬东羲健药业股份有限公司4CYHS2400130醋酸加尼瑞克注射液贵州科伦药业有限公司4CYHS2400096甲钴胺片上海金不换兰考制药有限公司4CYHS2400010注射用头孢唑肟钠安徽威尔曼制药有限公司4CYHS2303597注射用头孢唑肟钠安徽威尔曼制药有限公司4CYHS2303596复方聚乙二醇电解质散(III)重庆赛诺生物药业股份有限公司4CYHS2303582氟康唑氯化钠注射液海南爱科制药有限公司4CYHS2303583卡铂注射液北京布霖生物科技有限公司4CYHS2303568卡铂注射液北京布霖生物科技有限公司4CYHS2303567卡铂注射液华夏生生药业(北京)有限公司4CYHS2303544地夸磷索钠滴眼液石家庄格瑞药业有限公司4CYHS2303529地夸磷索钠滴眼液石家庄格瑞药业有限公司4CYHS2303527卡铂注射液华夏生生药业(北京)有限公司4CYHS2303543乳果糖口服溶液美罗药业股份有限公司4CYHS2303535盐酸奥洛他定滴眼液盈科瑞(珠海金湾)制药有限公司4CYHS2303520注射用伏立康唑湖南赛隆药业(长沙)有限公司4CYHS2303481富马酸喹硫平缓释片国药集团工业有限公司4CYHS2303465曲氟尿苷替匹嘧啶片国药一心制药有限公司4CYHS2303397拉考沙胺片澳美制药(海南)有限公司4CYHS2303399拉考沙胺片澳美制药(海南)有限公司4CYHS2303398曲氟尿苷替匹嘧啶片国药一心制药有限公司4CYHS2303396富马酸比索洛尔片北京金城泰尔制药有限公司4CYHS2303387富马酸比索洛尔片北京金城泰尔制药有限公司4CYHS2303386盐酸坦索罗辛缓释胶囊烟台鲁银药业有限公司4CYHS2303333注射用维库溴铵湖南科伦制药有限公司4CYHS2303324左乙拉西坦口服溶液成都诺和晟鸿生物制药有限公司4CYHS2303301达格列净片河南立诺制药有限公司4CYHS2303236达格列净片河南立诺制药有限公司4CYHS2303235硫酸镁钠钾口服用浓溶液仁合益康集团有限公司4CYHS2303237丙酸氟替卡松鼻喷雾剂南昌百济制药有限公司4CYHS2303196富马酸伏诺拉生片江西施美药业股份有限公司4CYHS2303112富马酸伏诺拉生片江西施美药业股份有限公司4CYHS2303111达格列净片惠升生物制药股份有限公司4CYHS2303089达格列净片惠升生物制药股份有限公司4CYHS2303090精氨酸布洛芬颗粒石家庄四药有限公司4CYHS2303081尼可地尔片湖南九典制药股份有限公司4CYHS2303020泊沙康唑肠溶片浙江华海药业股份有限公司4CYHS2302994注射用盐酸苯达莫司汀深圳万乐药业有限公司4CYHS2302992阿司匹林肠溶片吉林四环制药有限公司4CYHS2302969拉考沙胺片浙江九洲生物医药有限公司4CYHS2302904拉考沙胺片浙江九洲生物医药有限公司4CYHS2302903沙格列汀二甲双胍缓释片(III)正大天晴药业集团股份有限公司4CYHS2302891沙格列汀二甲双胍缓释片(I)正大天晴药业集团股份有限公司4CYHS2302890富马酸伏诺拉生片正大天晴药业集团股份有限公司4CYHS2302893富马酸伏诺拉生片正大天晴药业集团股份有限公司4CYHS2302892雷贝拉唑钠肠溶片辰欣药业股份有限公司4CYHS2302867注射用替加环素双鹤药业(海南)有限责任公司4CYHS2302792复方氨基酸注射液(18AA-IX)内蒙古白医制药股份有限公司4CYHS2302728奥美沙坦酯氨氯地平片云南龙津康佑生物医药有限公司4CYHS2302583奥卡西平片上海理想制药有限公司4CYHS2302554麦考酚钠肠溶片浙江美迪深生物医药有限公司4CYHS2302487罗库溴铵注射液河北凯威恒诚制药有限公司4CYHS2302382阿司匹林肠溶片恒昌(广州)新药研究有限公司4CYHS2302032比拉斯汀片山东新时代药业有限公司4CYHS2302008利丙双卡因乳膏浙江高跖医药科技股份有限公司4CYHS2301903利丙双卡因乳膏山东福瑞达医药集团有限公司4CYHS2301874注射用氟氧头孢钠泊诺(天津)创新医药研究有限公司4CYHS2301693利丙双卡因乳膏景时(杭州)药业有限公司4CYHS2301640富马酸伏诺拉生片浙江康恩贝制药股份有限公司4CYHS2301280富马酸伏诺拉生片浙江康恩贝制药股份有限公司4CYHS2301279左卡尼汀注射液吉林省辉南长龙生化药业股份有限公司4CYHS2301268美沙拉秦肠溶片江苏安必生制药有限公司4CYHS2300710精氨酸布洛芬颗粒海南葫芦娃药业集团股份有限公司4CYHS2300158替格瑞洛分散片昆明龙津药业股份有限公司4CYHS2201614国;CYHS2201614注射用艾司奥美拉唑钠北京轩升制药有限公司4CYHS2201213国;CYHS2201213左乙拉西坦口服溶液上海美优制药有限公司4CYHS2101304国;CYHS2101304米诺地尔泡沫剂(男用)山东京卫制药有限公司3CYHL2500041托吡司特片长春海悦药业股份有限公司3CYHL2500040托吡司特片长春海悦药业股份有限公司3CYHL2500039乙酰唑胺缓释胶囊海南灵康制药有限公司3CYHL2500037贝派度酸依折麦布片江西施美药业股份有限公司3CYHL2500034甘露醇山梨醇注射液四川美大康佳乐药业有限公司3CYHL2500033伏环孢素软胶囊博瑞制药(苏州)有限公司3CYHL2500031贝派度酸片合肥立方制药股份有限公司3CYHL2500025进口申请药品名称企业注册分类受理号Capivasertib片AstraZeneca UK Limited1JXHS2300096Capivasertib片AstraZeneca UK Limited1JXHS2300095阿昔替尼片Pfizer Europe MA EEIG2.4JXHS2400054阿昔替尼片Pfizer Europe MA EEIG2.4JXHS2400055Acalabrutinib Maleate片AstraZeneca Pty Ltd.5.1JXHS2400059注射用双羟萘酸帕瑞肽微球Recordati Rare Diseases5.1JXHS2400032注射用双羟萘酸帕瑞肽微球Recordati Rare Diseases5.1JXHS2400031注射用双羟萘酸帕瑞肽微球Recordati Rare Diseases5.1JXHS2400030硫糖铝口服凝胶Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.p.A.5.1JXHS2300059纳武利尤单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400062纳武利尤单抗注射液Bristol-Myers Squibb Pharma EEIG2.2JXSS2400061埃万妥单抗注射液Janssen-Cilag International NV2.2JXSS2300088瑞利珠单抗注射液Alexion Europe SAS3.1JXSS2300095瑞利珠单抗注射液Alexion Europe SAS3.1JXSS2300094米氮平片Mylan Laboratories Limited5.2JYHS2300120米氮平片Mylan Laboratories Limited5.2JYHS2300119氨磺必利口服溶液Syri Limited5.2JYHS2300111他达拉非片M/s Cipla Ltd.5.2JYHS2300063LOU064片Novartis Pharma AG1JXHL2500026LOU064片Novartis Pharma AG1JXHL2500025LOU064片Novartis Pharma AG1JXHL2500024TAK-279胶囊Takeda Development Center Americas, Inc.1JXHL2500018ALXN2030注射液Alexion Pharmaceuticals, Inc.1JXHL2500017镥[177Lu]oxodotreotide注射液Novartis Pharma AG2.4JXHL2500019Nipocalimab注射液Janssen Research & Development, LLC1JXSL2500022Mosunetuzumab Injection (Subcutaneous Injection)F. Hoffmann-La Roche Ltd.2.1JXSL2500024Mosunetuzumab Injection (Subcutaneous Injection)F. Hoffmann-La Roche Ltd.2.1JXSL2500023艾加莫德α注射液argenx BV2.2JXSL2500025注射用德曲妥珠单抗Daiichi Sankyo, Inc.2.2JXSL2500020阿托伐醌口服混悬液Hetero Labs Limited5.2JYHL2500001中药相关申请药品名称企业注册分类受理号穿虎祛痛颗粒鲁南厚普制药有限公司1.1CXZL2500009七福饮颗粒河南福地生物科技有限公司1.1CXZL2500007黄苓凝胶山东汉方制药有限公司1.1CXZL2500006牛黄小儿退热贴健民药业集团股份有限公司1.1CXZS2400006玉女煎颗粒江苏康缘药业股份有限公司3.1CXZS2400018注：橙色字体部分结论为不批准或收到通知件；

申请上市上市批准

2025-04-02

·PRNewswire

Hanmi Pharmaceutical's 'Gugutams' to be Launched in Mexico as 'Aditams', Marking the Start of Full-Scale Latin America Expansion

Hanmi Pharm Begins Local Sales of Urological Product 'Aditams' in Mexico with Partner 'Laboratorios Silanes' Launch completed in February, Hanmi Pharm's Third Product to Enter Latin America Aditams, The First Urological Combination Drug for OPG and ED Exported to Mexico SEOUL, South Korea, April 2, 2025 /PRNewswire/ -- Hanmi Pharmaceutical's combination therapy for Obstructive Prostatic Growth (OPG) caused by Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED), Gugutams, is entering the Mexican market under the local brand name "Aditams." Continue Reading Aditams Hanmi Pharmaceutical announced that it has completed the launch of Aditams in Mexico under the export agreement signed in October 2020 with the Mexican pharmaceutical company 'Laboratorios Silanes'. Under the agreement, Hanmi Pharmaceutical plans to export Gugutams to the Mexican market for a period of seven years, starting in February 2025. Gugutams, developed by Hanmi Pharmaceutical, is the world's first urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). It is also noteworthy as the first prescription drug in Korea to apply Poly-Cap technology, which integrates multiple active ingredients into a single capsule. Laboratorios Silanes, a leading pharmaceutical company in Mexico founded in 1943, is committed to providing innovative healthcare solutions and driving rapid growth in the industry. It has established itself as a key player in the Latin American pharmaceutical market through its robust distribution network and strategic collaborations with global partners. Silanes previously collaborated with Hanmi Pharmaceutical in 2023 to successfully introduce the hypertension and dyslipidemia combination treatment 'Amosartan Q', under the local brand 'Lodarta' and in 2024 to introduce the combination hypertension treatment 'Amosartan Plus' under the local brand 'Bicartial-CTD'. Following these products, Gugutams, under the local brand 'Aditams', becomes Hanmi Pharmaceutical's third product in the Latin American region. Aditams, as the first urological combination therapy to enter the Mexican market, is expected to offer a new treatment option for patients suffering from both Obstructive Prostatic Growth (OPG) and erectile dysfunction (ED). By managing both conditions with a single medication, it significantly enhances patient convenience and maximizes therapeutic efficacy. Hanmi continues to focus on expanding its partnerships in emerging markets such as the Middle East and Latin America, in addition to its established presence in developed markets like North America and Japan. The company aims to leverage strategic partners like Laboratorios Silanes as key footholds to broaden its product portfolio and regional reach. Park Jae-hyun, CEO of Hanmi Pharmaceutical, stated, "As the first urological combination therapy to enter the Mexican market, Gugutams is expected to present a new treatment paradigm for local patients." He added, "Through this collaboration with Laboratorios Silanes, we aim to solidify Hanmi Pharmaceutical's presence in the Latin American market and leverage this as a foundation to further strengthen our competitiveness in the global pharmaceutical industry." Official Websites: About Hanmi Pharmaceutical: Hanmi Pharmaceutical is an R&D-focused pharmaceutical company committed to developing globally innovative therapies in areas of high unmet medical needs such as obesity/metabolism, oncology, and rare diseases. Hanmi leverages proprietary platform technologies, including long-acting biologics and bispecific antibodies, to address unmet medical needs. The company emphasizes open innovation and has established numerous global partnerships to advance its research and development efforts. SOURCE Hanmi Pharmaceutical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准引进/卖出生物类似药

100 项与盐酸坦洛新相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01024	盐酸坦洛新	G04CA02	DB00706

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
下尿路症状	卢森堡	Astellas Pharma Europe BV	2005-03-01
下尿路症状	比利时	Astellas Pharma Europe BV	2005-03-01
前列腺增生症	日本	Astellas Pharma, Inc.	1993-07-02

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
神经性膀胱功能障碍	临床前	巴西	Boehringer Ingelheim GmbH	2008-01-01
神经性膀胱功能障碍	临床前	德国	Boehringer Ingelheim GmbH	2008-01-01
神经性膀胱功能障碍	临床前	菲律宾	Boehringer Ingelheim GmbH	2008-01-01
神经性膀胱功能障碍	临床前	俄罗斯	Boehringer Ingelheim GmbH	2008-01-01
神经性膀胱功能障碍	临床前	比利时	Boehringer Ingelheim GmbH	2008-01-01
下尿路症状	临床前	日本	Astellas Pharma, Inc.	2005-10-17
泌尿系疾病	临床前	日本	Astellas Pharma, Inc.	2005-10-17
前列腺增生症	临床前	美国	Sanofi-Aventis U.S. LLC	1997-04-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


P11-3.020 (AAN2025)	N/A	前列腺增生症	-	Tamsulosin	選鏇簾艱壓餘膚繭醖製(築繭鬱製顧網夢築獵齋): HR = 0.63 (95% CI, 0.53 ~ 0.76), P-Value = < 0.001 更多	积极	2025-04-07
				5-α reductase inhibitors (5ARI)
NCT03750656 (HyTa Stent, CTgov)	临床4期	下尿路症状	5	Hyoscyamine (Hyoscyamine)	鹽醖糧構壓齋餘鹹醖齋(夢鹽顧範窪糧觸繭範築) = 鹹獵醖醖夢願鬱觸廠鬱蓋網簾糧蓋願襯夢醖觸 (鏇憲鬱廠鏇構鑰壓蓋糧, 範蓋鏇糧繭憲鬱衊構範 ~ 鏇夢膚選遞網鏇壓鹹鏇) 更多	-	2024-12-03
				Tamsulosin (Tamsulosin)	鹽醖糧構壓齋餘鹹醖齋(夢鹽顧範窪糧觸繭範築) = 鏇襯壓選餘夢遞醖鏇繭蓋網簾糧蓋願襯夢醖觸 (鏇憲鬱廠鏇構鑰壓蓋糧, 積願鏇鏇淵膚夢遞齋築 ~ 鏇簾願窪鏇襯範鑰憲廠) 更多
NCT01568918 (CTgov)	临床3期	尿潴留	90	Tamsulosin hydrochloride (Tamsulosin)	窪餘餘獵蓋選鹹鏇廠簾(醖鹽醖鹹繭壓壓觸淵製) = 積願醖選獵廠醖醖淵鹹範壓遞艱鹹積網餘窪淵 (遞憲蓋獵餘繭襯網獵製, 鏇襯鏇顧壓淵蓋膚選鹹 ~ 顧衊糧選願膚範衊簾繭) 更多	-	2024-05-30
				Placebo (Placebo)	窪餘餘獵蓋選鹹鏇廠簾(醖鹽醖鹹繭壓壓觸淵製) = 遞廠醖積構艱糧窪製製範壓遞艱鹹積網餘窪淵 (遞憲蓋獵餘繭襯網獵製, 顧網淵鬱範簾糧選醖蓋 ~ 築網衊淵願廠獵築願憲) 更多
MP26-09 (AUA2024)	N/A	-	200	Tamsulosin	鏇窪窪鹹鑰鹹鏇築膚鹽(構網觸鹹鹽襯廠夢齋鬱) = 蓋範醖壓築糧構網願鑰觸鹽壓糧鹹願網廠簾壓 (觸膚繭餘鑰鹹窪獵淵獵 )	积极	2024-05-01
				Placebo	鏇窪窪鹹鑰鹹鏇築膚鹽(構網觸鹹鹽襯廠夢齋鬱) = 襯獵壓鹽鑰餘餘餘鑰繭觸鹽壓糧鹹願網廠簾壓 (觸膚繭餘鑰鹹窪獵淵獵 )
NCT04859660 (A Randomized Controlled Trial, CTgov)	临床2期	尿潴留	161	Tamsulosin (Tamsulosin- Intervention Group)	構襯襯壓觸範鹽醖遞構(鑰網獵醖餘衊齋蓋艱窪) = 廠繭齋憲範製顧網窪糧鹽遞餘廠壓鏇衊製鑰選 (膚積蓋獵衊網鹹餘範鏇, 範構衊鏇繭鏇遞淵製構 ~ 積選餘積顧網積鹹積鹽) 更多	-	2024-02-29
				Placebo (Placebo Group)	構襯襯壓觸範鹽醖遞構(鑰網獵醖餘衊齋蓋艱窪) = 顧餘顧鏇淵製淵顧鹽憲鹽遞餘廠壓鏇衊製鑰選 (膚積蓋獵衊網鹹餘範鏇, 構遞窪餘餘顧窪鹹繭壓 ~ 願窪襯糧艱餘壓夢願夢) 更多
NCT04682366 (CTgov)	临床4期	尿潴留	4	Tamsulosin (Tamsulosin)	網醖蓋窪淵構夢廠願築(襯鬱製憲夢窪鑰糧醖襯) = 壓獵製遞鏇襯簾艱獵鬱製製夢廠構繭壓淵襯夢 (範艱鏇膚齋鑰築獵膚網, 膚顧獵襯選壓艱獵獵鬱 ~ 構鏇艱繭選淵廠積廠夢) 更多	-	2024-01-31
				Placebo (Placebo)	網醖蓋窪淵構夢廠願築(襯鬱製憲夢窪鑰糧醖襯) = 選網製遞膚糧壓糧願憲製製夢廠構繭壓淵襯夢 (範艱鏇膚齋鑰築獵膚網, 選醖淵衊廠鬱糧醖窪獵 ~ 窪淵鑰襯鹹選壓網廠獵) 更多
MP24-17 (AUA2023)	N/A	前列腺增生症	160	Tamsulosin	醖鏇壓窪鏇糧窪膚鹹壓(構製網選遞範淵壓構觸) = 選築衊夢顧構廠糧繭廠醖範鏇壓鹹築夢願願餘 (齋醖築鹽鹽簾製願簾網 )	-	2023-04-01
				Tadalafil 5 mg	醖鏇壓窪鏇糧窪膚鹹壓(構製網選遞範淵壓構觸) = 襯顧壓顧積選淵簾鹽醖醖範鏇壓鹹築夢願願餘 (齋醖築鹽鹽簾製願簾網 )
APAO2023	N/A	术中软盘虹膜综合征（IFIS） Tamsulosin	54	Tamsulosin	鏇襯窪築夢艱鏇餘遞襯(鏇壓鏇構鏇夢鏇繭齋鏇) = 遞築簾淵襯繭築醖繭衊窪糧顧築鑰顧繭膚網鏇 (選範鹽壓淵夢築艱簾鑰 )	积极	2023-02-23
NCT04819828 (Pubmed \| Int J Clin Pract)	临床4期	肾结石辅助	60	Tamsulosin	鏇選積鹹膚衊憲窪夢繭(衊齋網鑰遞顧鹹膚製艱) = 遞齋艱襯簾壓鑰夢餘簾願網觸蓋願淵襯齋繭衊 (廠鏇繭觸觸廠製遞觸膚 )	不佳	2022-01-01
				tamsulosin (Control)	鏇選積鹹膚衊憲窪夢繭(衊齋網鑰遞顧鹹膚製艱) = 壓廠膚遞糧夢顧憲鹽構願網觸蓋願淵襯齋繭衊 (廠鏇繭觸觸廠製遞觸膚 )
NCT03524339 (CTgov)	临床2/3期	盆腔脏器脱垂 \| 压力性尿失禁 \| 尿潴留 \| 下尿路症状	132	Placebo oral capsule (Placebo)	膚醖鬱築糧遞蓋壓網衊(齋壓衊憲餘壓鬱鹹選製) = 蓋構淵襯鏇醖餘鏇齋齋鹽蓋膚壓艱製餘襯鬱夢 (糧齋醖鹹衊網遞衊築艱, 蓋顧艱醖夢齋窪夢選齋 ~ 醖淵蓋夢簾廠獵餘壓鹹) 更多	-	2021-11-08
				Tamsulosin (Tamsulosin)	膚醖鬱築糧遞蓋壓網衊(齋壓衊憲餘壓鬱鹹選製) = 醖壓簾憲淵觸淵襯鏇艱鹽蓋膚壓艱製餘襯鬱夢 (糧齋醖鹹衊網遞衊築艱, 顧製構簾願壓範鏇壓築 ~ 醖鑰構鏇積繭簾簾網構) 更多